CN1679831A - Oral medicine for cardio-cerebral blood vessel diseases and its making method - Google Patents
Oral medicine for cardio-cerebral blood vessel diseases and its making method Download PDFInfo
- Publication number
- CN1679831A CN1679831A CN 200510041653 CN200510041653A CN1679831A CN 1679831 A CN1679831 A CN 1679831A CN 200510041653 CN200510041653 CN 200510041653 CN 200510041653 A CN200510041653 A CN 200510041653A CN 1679831 A CN1679831 A CN 1679831A
- Authority
- CN
- China
- Prior art keywords
- flos carthami
- extract
- radix salviae
- salviae miltiorrhizae
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
An orally taken Chinese medicine for treating cardiovascular and cerebrovascular diseases (coronary heart disease and apoplexy for example) is prepared from red sage root and safflower through extracting their active components and dispensing the medicine.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine, more particularly, relate to a kind ofly, belong to medical technical field with Radix Salviae Miltiorrhizae, two kinds of Chinese herbal medicine of Flos Carthami oral drugs that are the raw material for treating cardiovascular and cerebrovascular disease and preparation method thereof.
Background technology
Cardiovascular and cerebrovascular disease is commonly encountered diseases, frequently-occurring disease, sickness rate height, disability rate height, mortality rate height, thereby be the disease of a kind of serious harm human health and life, domestic and social life is exerted a certain influence.Many scholars are in treatment and the prevention of exploring cardiovascular and cerebrovascular disease both at home and abroad.Motherland's medicine and pharmacology are being brought into play positive effect owing to determined curative effect, toxic and side effects are little aspect treatment and the prevention cardiovascular and cerebrovascular disease.By Radix Salviae Miltiorrhizae, two kinds of Chinese herbal medicine of Flos Carthami is " DANHONG ZHUSHEYE ", " DANHONG drip liquid ", the determined curative effect rapid in onset aspect the acute cardiovascular and cerebrovascular disease rescue that raw material is made, be widely used clinically, recorded in National Drug Administration's " national standard for traditional Chinese medicines compilation " (Chinese patent medicine provincial standard rising national standard part-internal medicine is felt concerned about fascicle).But because cardiovascular and cerebrovascular disease is chronic disease, need the long-term prescription treatment, thus the medication inconvenience of drug administration by injection especially the cardiovascular and cerebrovascular disease patient can not make the use of injection be subjected to certain restriction by own injecting drug use.Press for clinically that steady quality, determined curative effect, dose are little, the oral drug preparation of the treatment cardiovascular and cerebrovascular disease of taking convenience.Still the development report that does not have at present oral formulation of danshensu and safflower yellow.
Summary of the invention
The objective of the invention is to overcome the deficiencies in the prior art, a kind of oral drug preparation that is the raw material for treating cardiovascular and cerebrovascular disease with Radix Salviae Miltiorrhizae, two kinds of Chinese herbal medicine of Flos Carthami is provided, little, the taking convenience of this oral drugs dose, and rapid-action, determined curative effect, almost non-toxic side effect.
Another object of the present invention is to provide the above-mentioned preparation method that is the oral drug preparation of raw material for treating cardiovascular and cerebrovascular disease with Radix Salviae Miltiorrhizae, two kinds of Chinese herbal medicine of Flos Carthami.
The oral drug preparation of treatment cardiovascular and cerebrovascular disease provided by the invention is made up of and materials of weight proportions is made medicament following: Radix Salviae Miltiorrhizae 12～30, Flos Carthami 4～12.
The oral drug preparation of treatment cardiovascular and cerebrovascular disease provided by the invention, raw material composition and weight proportion are preferably: Radix Salviae Miltiorrhizae 14～24, Flos Carthami 6～9.
The oral drug preparation of treatment cardiovascular and cerebrovascular disease of the present invention, best raw material is formed and weight proportion is: Radix Salviae Miltiorrhizae 21, Flos Carthami 7.
The oral drugs of treatment cardiovascular and cerebrovascular disease of the present invention can be made said multiple dosage form on the pharmaceutics, as capsule, tablet, granule, soft capsule, drop pill, mixture, syrup etc.
The preparation method of above-mentioned treatment cardiovascular and cerebrovascular disease oral drug preparation may further comprise the steps:
(1) get red rooted salvia, clean system is ground into coarse granule, with 20%～60% ethanol percolate extraction of 10～40 times of weight of medical material, collect percolate, decompression recycling ethanol, leave standstill, filter, filtrate decompression is concentrated into relative density 1.05～1.23, adds ethanol and makes and contain alcohol amount and reach 60%～85%, leaves standstill, filter, decompression recycling ethanol also concentrates, and drying gets Radix Salviae Miltiorrhizae extract;
(2) get flos carthami, clean system uses the water retting of 6～30 times of weight of medical material to extract 1～4 time, each 1～12 hour, filter, merging filtrate is evaporated to relative density 1.05～1.28, adding ethanol makes and contains alcohol amount and reach 50%～85%, leave standstill, filter, decompression recycling ethanol also concentrates, drying gets Flos Carthami extract;
(3) get above-mentioned Radix Salviae Miltiorrhizae extract, Flos Carthami extract, add pharmaceutic adjuvant, make capsule, tablet, granule, soft capsule, drop pill, mixture, syrup by the medicament common process, promptly.
Pharmaceutic adjuvant described in the present invention is the common medicinal supplementary material on the pharmaceutics, as prepare tablet and capsule filler commonly used such as starch, dextrin, Icing Sugar, lactose, calcium carbonate etc., disintegrating agent such as dry starch, carboxymethyl starch sodium, cross-linked pvp etc., lubricant such as magnesium stearate, Pulvis Talci, Macrogol 4000 or 6000 etc.; Adjuvant that the preparation granule is commonly used such as Icing Sugar, mannitol, lactose, soluble starch, dextrin etc.; One or more of the adjuvant of preparation soft capsule such as vegetable oil, Cera Flava, parabens, Tween 80, liquid macrogol, phospholipid etc.; Polyethylene Glycol series, PVPk30, stearic acid etc. such as preparation adjuvant of drop pill such as polyethylene glycol 6000, Macrogol 4000, Polyethylene Glycol 12000 one or more; The adjuvant of mixture and syrup such as correctives white sugar, steviosin, cyclamate, A Siba are sweet, essence, dextrin etc., stabilizing agent such as different Vc sodium, sodium sulfite, EDTA etc.; Radix Salviae Miltiorrhizae and Flos Carthami raw material used in the present invention requires to meet respectively " relevant every regulation under each Chinese medicine item of Chinese pharmacopoeia version in 2000.
Beneficial effect of the present invention:
1, the present invention changes oral formulations into " DANHONG ZHUSHEYE ", taking convenience, be easy to carry about with one transportation and storage, the needs of chronic disease patient's long-term prescriptions such as suitable cardiovascular and cerebrovascular vessel.
2, good stability: the present invention changes solid orally ingestible and liquid oral medicine into " DANHONG ZHUSHEYE ", has improved the stability of effective ingredient.Effective ingredient Flos Carthami total flavone in the effective ingredient Radix Salviae Miltiorrhizae total phenolic acids and Flos Carthami in the Radix Salviae Miltiorrhizae under aqueous solution state, less stable.The present invention has added stabilizing agent such as different Vc sodium, sodium sulfite, EDTA sodium etc. in liquid oral medicine, can prevent the oxidation Decomposition of effective ingredient.Show that through stability test the effect duration of liquid of the present invention and solid orally ingestible is all more than 2.8 years, and the effect duration of DANHONG ZHUSHEYE is 1.9 years, has improved the stability of preparation containing red sange root and safflower greatly.
3, effective component extraction rate height of the present invention.One of raw material of the present invention Radix Salviae Miltiorrhizae, main effective ingredient is water miscible phenolic acidsization and thing, especially under the situation of being heated for a long time, poor stability easily decomposes specific examples of such components, causes the active constituent content reduction, drug effect decline in aqueous solution.And in extraction process of the present invention, adopt ethanol percolate extraction, the low-temperature reduced-pressure of low concentration to reclaim to Radix Salviae Miltiorrhizae to concentrate, drying under reduced pressure or spray-dired preparation method, effectively extract and kept the liposoluble ingredient in the Radix Salviae Miltiorrhizae, compare with the water boiling and extraction technology of former DANHONG ZHUSHEYE, through using high performance liquid chromatography [You Yongji etc., Chinese Pharmaceutical Journal, 2003,38 (12) 950]] detect, the results are shown in following table:
Table 1 Different Extraction Method is to the extraction ratio of effective component in red sage
| Extracting method | Active constituent content (%) | |||
| Salvianolic acid B | Danshensu sodium | Protocatechualdehyde | ||
| Decocting 2 times each 1.5 hours, adds 10 times/time in water | ????3.19 | ???0.331 | ????0.049 | |
| 50% alcohol reflux 2 times, each 1.5 hours, 10 times/time of solubilizers | ????4.11 | ???0.139 | ????0.006 | |
| Percolation (20 times of amount solvents) | 20% ethanol, 35% ethanol, 50% ethanol, 60% ethanol | ????4.47 ????4.74 ????4.71 ????4.73 | ???0.204 ???0.119 ???0.068 ???0.061 | ????0.0073 ????0.0036 ????0.0039 ????0.0037 |
Table 1 shows that close with 50% alcohol reflux effect with the 20-60% ethanol percolate extraction, the content of the main effective ingredient salvianolic acid B of the Radix Salviae Miltiorrhizae that percolation proposes exceeds more than 40% than decocting method, obviously is better than decocting method.But owing to the oil-soluble impurities that goes out with 50% alcohol reflux is more, influence follow-up impurity removal process, therefore select the 20-60% ethanol percolate extraction for use.
4, production technology is simple, is fit to big production.20-60% ethanol percolate extraction Radix Salviae Miltiorrhizae that the present invention adopts and water retting method are extracted technology and concentrating under reduced pressure, drying under reduced pressure or the drying process with atomizing of Flos Carthami, are conventional production process, and general pharmaceutical factory can both produce, thereby the invention process is strong.
5, determined curative effect.Show through the test of animal pharmacodynamics, the present invention have alleviate cerebrovascular permeability and brain water content, inhibition thrombosis, obviously cerebral blood flow increasing amount, thrombus, anticoagulant, minimizing rabbit myocardial infarction area, reduce the blood vessel total peripheral resistance, increase the effect of heart coronary flow, show for cardiovascular and cerebrovascular disease such as apoplexy and coronary heart disease to have better therapeutic effect.
The Pharmacodynamic test of active extract conclusion
1, to the influence of rat experiment cerebral ischemia
Cerebral ischemia has significant protective effect to rat experiment in the present invention; obviously improve pathological change such as cerebrovascular permeability and brain water content increase due to the cerebral ischemia; heavy dose of group reduces cerebral index and brain water content all is better than the heavy dose of group of FUFANG DANSHEN PIAN, and the degree that heavy dose of group is improved cerebral ischemia also is better than the FUFANG DANSHEN PIAN group.
2, to the influence of anesthetized dog cerebral blood flow
The present invention and FUFANG DANSHEN PIAN all can significantly increase the anesthetized dog cerebral blood flow, but heavy dose of group is organized the effect of cerebral blood flow increasing amount through statistical procedures, there was no significant difference with FUFANG DANSHEN PIAN is heavy dose of.
3, the dissolution of rat artery thrombosis
Cross the therapeutic administration, observed result shows that the present invention has tangible dissolution to thrombosis, and the dissolution degree of heavy dose of group thrombosis is better than the heavy dose of group of FUFANG DANSHEN PIAN.
4, to the thrombotic influence of rat artery
The present invention has the effect that delays thrombus formation time, and heavy dose of group delays thrombotic effect and is better than the heavy dose of group of FUFANG DANSHEN PIAN.
5, ADP is induced the influence of rat platelet aggregation
The present invention can obviously reduce platelet aggregation, prolongs the platelet aggregation time, and heavy dose of group induces the effect of rat platelet aggregation to be better than the heavy dose of group of FUFANG DANSHEN PIAN for suppressing ADP.
6, to the influence of anesthetized dog heart Peripheral resistance and arteria coronaria flow
The present invention can reduce the blood vessel total peripheral resistance, increases the heart coronary flow, and blood supply improves under the endocardium thereby make.The effect that heavy dose of group increases the heart coronary flow is better than the heavy dose of group of FUFANG DANSHEN PIAN, and the effect that heavy dose of group reduces the blood vessel total peripheral resistance obviously is better than the heavy dose of group of FUFANG DANSHEN PIAN.
7, to the influence of rabbit acute myocardial infarction area
The present invention can significantly dwindle the rabbit myocardial infarction area, and acute myocardial infarction is had preventive and therapeutic effect, and heavy dose of group is better than the heavy dose of group of FUFANG DANSHEN PIAN for the effect that reduces rabbit acute myocardial infarction area.
The specific embodiment
The preparation of embodiment 1 tablet
(1) get red rooted salvia 1200g, clean system is ground into coarse granule, with 30% ethanol percolate extraction of 30 times of weight of medical material, collect percolate, decompression recycling ethanol, leave standstill, filter, filtrate decompression is concentrated into relative density 1.18 (55 ℃), adds ethanol and makes and contain alcohol amount and reach 60%, leaves standstill, filter, decompression recycling ethanol also is concentrated into relative density 1.14 (55 ℃), and spray drying gets Radix Salviae Miltiorrhizae extract;
(2) get flos carthami 400g, clean system, under agitation (120r/min) extracts 3 times with water retting, each water, dipping 2 hours with 10 times of weight of medical material, filter, merging filtrate is evaporated to relative density 1.15 (60 ℃), adding ethanol makes and contains alcohol amount and reach 50%, leave standstill, filter, decompression recycling ethanol also is concentrated into relative density 1.16 (55 ℃), spray drying gets Flos Carthami extract;
(3) get above-mentioned Radix Salviae Miltiorrhizae extract, Flos Carthami extract, add starch 50g,, granulate with 80% ethanol system soft material, dry, granulate, the carboxymethyl starch sodium of adding 15g micropowder silica gel and 10g, mixing, tabletting, the bag film-coat promptly makes tablet of the present invention.
The preparation of embodiment 2 capsules
(1) get red rooted salvia 2600g, clean system is ground into coarse granule, with 35% ethanol percolate extraction of 25 times of weight of medical material, collect percolate, decompression recycling ethanol, centrifugal filtration, filtrate decompression is concentrated into relative density 1.12 (55 ℃), adds ethanol and makes and contain alcohol amount and reach 65%, leaves standstill, filter, decompression recycling ethanol also is concentrated into relative density 1.13 (55 ℃), and spray drying gets Radix Salviae Miltiorrhizae extract;
(2) get flos carthami 1200g, clean system, under agitation (100r/min) extracts 4 times with water retting, each water with 6 times of weight of medical material, dipping 10 hours filter merging filtrate, be evaporated to relative density 1.16 (60 ℃), add ethanol and make and contain alcohol amount and reach 60%, leave standstill, filter, decompression recycling ethanol also is condensed into thick paste, drying under reduced pressure is ground into fine powder, gets Flos Carthami extract;
(3) get above-mentioned Radix Salviae Miltiorrhizae extract, Flos Carthami extract, add starch 50g, with 85% ethanol system soft material, granulate, dry, granulate add the 10g magnesium stearate, and mixing is encapsulated, promptly makes capsule of the present invention.
The preparation of embodiment 3 tablets
(1) get red rooted salvia 1600g, clean system is ground into coarse granule, with 25% ethanol percolate extraction of 35 times of weight of medical material, collect percolate, decompression recycling ethanol, leave standstill, filter, filtrate is evaporated to relative density 1.15 (60 ℃) in about 50 ℃, adds ethanol and makes and contain alcohol amount and reach 65%, leave standstill, filter, decompression recycling ethanol also concentrates drying under reduced pressure, be ground into fine powder, get Radix Salviae Miltiorrhizae extract;
(2) get flos carthami 900g, clean system uses the water retting of 21 times of weight of medical material to extract 3 times, each 7 hours, filter, merging filtrate is evaporated to relative density 1.08 (65 ℃), adding ethanol makes and contains alcohol amount and reach 75%, leave standstill, filter, filtrate is in 60 ℃ of following decompression recycling ethanols and concentrated, spray drying gets Flos Carthami extract;
(3) get above-mentioned Radix Salviae Miltiorrhizae extract, Flos Carthami extract, add starch 50g, lactose 50g, mixing is used 80% alcohol granulation, dry, granulate, and the magnesium stearate of adding 15g cross-linked pvp and 8g, mixing, tabletting, the bag film-coat promptly makes tablet of the present invention.
The preparation of embodiment 4 granules
(1) get red rooted salvia 3000g, clean system is ground into coarse granule, with 40% ethanol percolate extraction of 40 times of weight of medical material, collect percolate, decompression recycling ethanol, leave standstill, filter, filtrate decompression is concentrated into relative density 1.13 (65 ℃), adds ethanol and makes and contain alcohol amount and reach 60%, leave standstill, filter, decompression recycling ethanol also is concentrated into relative density 1.38 (65 ℃), drying under reduced pressure, be ground into fine powder, get Radix Salviae Miltiorrhizae extract;
(2) get flos carthami 1200g, clean system, under agitation (150r/min) extracts 3 times with the water retting of 15 times of weight of medical material, each 4 hours, filter merging filtrate, be evaporated to relative density 1.18 (60 ℃), add ethanol and make and contain alcohol amount and reach 85%, leave standstill, filter, decompression recycling ethanol also is concentrated into relative density 1.34 (65 ℃), drying under reduced pressure is pulverized, and gets Flos Carthami extract;
(3) get above-mentioned Radix Salviae Miltiorrhizae extract, Flos Carthami extract, add mannitol 130g, soluble dextrins 290g, betacyclodextrin 78g, mixing, the alcohol granulation with 75%, drying, granulate, packing, quality inspection promptly gets granule of the present invention.
The preparation of embodiment 5 drop pills
(1) get red rooted salvia 750g, clean system is ground into coarse granule, with 35% ethanol percolate extraction of 20 times of weight of medical material, collect percolate, decompression recycling ethanol, leave standstill, centrifugal filtration, filtrate decompression is concentrated into relative density 1.12 (65 ℃), adds ethanol and makes and contain alcohol amount and reach 75%, leave standstill, filter, decompression recycling ethanol also is condensed into thick paste, drying under reduced pressure, pulverize, get Radix Salviae Miltiorrhizae extract;
(2) get flos carthami 250g, clean system, under agitation (100r/min) extracts 3 times with water retting, the water retting of 10 times of weight of each usefulness medical material 5 hours, filter, merging filtrate is evaporated to relative density 1.18 (60 ℃), adding ethanol makes and contains alcohol amount and reach 65%, leave standstill, filter, decompression recycling ethanol also concentrates, spray drying gets Flos Carthami extract;
(3) get above-mentioned Radix Salviae Miltiorrhizae extract, Flos Carthami extract, add PEG6000 500g, PEG4000 400g, mixing at 85 ℃ of following heating and meltings, keeps temperature to drip system for 85 ℃, dropper mouth and liquid level distance are chosen between the 3-5cm, drip speed control built in 30-70 drip/minute between, medicine liquid droplet to dimethicone (15-17 ℃), is removed coolant, select ball, promptly make drop pill of the present invention.
The preparation of embodiment 6 soft capsules
(1) gets red rooted salvia 1500g, flos carthami 500g, prepare Radix Salviae Miltiorrhizae extract, Flos Carthami extract respectively by embodiment 5 steps (1), (2);
(2) get above-mentioned Radix Salviae Miltiorrhizae extract, Flos Carthami extract, mixing gets the DANHONG extract;
(3) get Cera Flava 10g, put in the 350g soybean oil, heat, be stirred to the dispersion mixing, get mixed liquor A;
(4) get the DANHONG extract, join in the mixed liquor A, fully mixing is crossed the colloid mill mill and is spared, and gets content;
(5) get gelatin 120g, sorbitol 10g, glycerol 36g and water 110g, put the vessel in heating dissolving, filter, filtrate adds mud and moors golden propyl ester 3g, curcumin 1g, abundant mixing, and after the vacuumize degassing, 60 ℃ of heat preservation for standby use get rubber liquid;
(6) get foregoing thing and rubber liquid, with the compression moulding of soft capsule production equipment, drying promptly makes soft capsule of the present invention.
The preparation of embodiment 7 mixture
(1) gets red rooted salvia 1400g, flos carthami 600g, prepare Radix Salviae Miltiorrhizae extract, Flos Carthami extract respectively by embodiment 4 steps (1), (2);
(2) get above-mentioned Radix Salviae Miltiorrhizae extract, Flos Carthami extract, mixing gets the DANHONG extract;
(3) get the DANHONG extract, with behind the 1700ml dissolved in distilled water, add different Vc sodium 20g, EDTA sodium 2 grams, cyclamate 3g, mud and moor golden 6g, after the stirring and dissolving, filter, filtrate adds water and adjusts volume to 2000ml, filters, and fill is sterilized, and promptly makes mixture of the present invention.
The preparation of embodiment 8 syrups
(1) gets red rooted salvia 1200g, flos carthami 400g, prepare Radix Salviae Miltiorrhizae extract, Flos Carthami extract respectively by embodiment 3 steps (1), (2);
(2) get above-mentioned Radix Salviae Miltiorrhizae extract, Flos Carthami extract, mixing gets the DANHONG extract;
(3) get the DANHONG extract, behind the 1600ml dissolved in distilled water, adding sodium sulfite 30g, EDTA sodium 2.3 grams, sucrose 500g, mud are moored golden 8g, after the stirring and dissolving, filter, filtrate adds water and adjusts volume to 2000ml, filters, fill, sterilization promptly makes syrup of the present invention.
Claims (5)
1, a kind of oral drugs for the treatment of cardiovascular and cerebrovascular disease is characterized in that it is made up of and medicament that materials of weight proportions is made following:
Radix Salviae Miltiorrhizae 12～30, Flos Carthami 4～12.
2, the oral drugs of treatment cardiovascular and cerebrovascular disease according to claim 1 is characterized in that it is made up of and medicament that materials of weight proportions is made following:
Radix Salviae Miltiorrhizae 14～24, Flos Carthami 6～9.
3, the oral drugs of treatment cardiovascular and cerebrovascular disease according to claim 2 is characterized in that it is made up of and medicament that materials of weight proportions is made following:
Radix Salviae Miltiorrhizae 21, Flos Carthami 7.
4,, it is characterized in that described medicament is capsule, tablet, granule, soft capsule, drop pill, mixture, syrup according to the oral drugs of claim 1,2 or 3 described treatment cardiovascular and cerebrovascular diseases.
5, the preparation method of the oral drugs of treatment cardiovascular and cerebrovascular disease as claimed in claim 4 is characterized in that may further comprise the steps:
(1) get red rooted salvia, clean system is ground into coarse granule, with 20%～60% ethanol percolate extraction of 10～40 times of weight of medical material, collect percolate, decompression recycling ethanol, leave standstill, filter, filtrate decompression is concentrated into relative density 1.05～1.23, adds ethanol and makes and contain alcohol amount and reach 60%～85%, leaves standstill, filter, decompression recycling ethanol also concentrates, and drying gets Radix Salviae Miltiorrhizae extract;
(2) get flos carthami, clean system uses the water retting of 6～30 times of weight of medical material to extract 1～4 time, each 1～12 hour, filter, merging filtrate is evaporated to relative density 1.05～1.28, adding ethanol makes and contains alcohol amount and reach 50%～85%, leave standstill, filter, decompression recycling ethanol also concentrates, drying gets Flos Carthami extract;
(3) get above-mentioned Radix Salviae Miltiorrhizae extract, Flos Carthami extract, add pharmaceutic adjuvant, make capsule, tablet, granule, soft capsule, drop pill, mixture, syrup by the medicament common process, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100416535A CN100386094C (en) | 2005-01-25 | 2005-01-25 | Oral medicine for cardio-cerebral blood vessel diseases and its making method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100416535A CN100386094C (en) | 2005-01-25 | 2005-01-25 | Oral medicine for cardio-cerebral blood vessel diseases and its making method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1679831A true CN1679831A (en) | 2005-10-12 |
| CN100386094C CN100386094C (en) | 2008-05-07 |
Family
ID=35066837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100416535A Active CN100386094C (en) | 2005-01-25 | 2005-01-25 | Oral medicine for cardio-cerebral blood vessel diseases and its making method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100386094C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058599A (en) * | 2009-11-17 | 2011-05-18 | 中国科学院上海药物研究所 | Salvianolate, and preparation method and application thereof |
| CN105250376A (en) * | 2015-11-30 | 2016-01-20 | 南京中医药大学 | Composition having gastric mucosa protecting effect and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1232273C (en) * | 2002-11-27 | 2005-12-21 | 咸阳步长医药科技发展有限公司 | Medicine compositions for treating cardiovascular cranialvascular disease, and its prepn. method |
-
2005
- 2005-01-25 CN CNB2005100416535A patent/CN100386094C/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058599A (en) * | 2009-11-17 | 2011-05-18 | 中国科学院上海药物研究所 | Salvianolate, and preparation method and application thereof |
| CN102058599B (en) * | 2009-11-17 | 2014-06-04 | 中国科学院上海药物研究所 | Salvianolate, and preparation method and application thereof |
| CN105250376A (en) * | 2015-11-30 | 2016-01-20 | 南京中医药大学 | Composition having gastric mucosa protecting effect and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100386094C (en) | 2008-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857681A (en) | Gastropathy treating preparation and its preparing process | |
| CN1943618A (en) | Red sage root effective part standard extract and its preparing method and use | |
| CN101045106A (en) | Traditional Chinese medicine for treating lung heat cough and high fever | |
| CN1923227A (en) | Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1679831A (en) | Oral medicine for cardio-cerebral blood vessel diseases and its making method | |
| CN1745809A (en) | Liuwei Dihuang effervescent tablet and its preparation thereof | |
| CN1070226C (en) | Gallnut oil and its extraction process and application in pharmacy | |
| CN1775263A (en) | Qiju-dihuang preparation and new preparation method | |
| CN1660420A (en) | Compound combination of Chinese traditional medicine in use for lowering viscosity of whole blood, thrombolysis and reducing blood fat | |
| CN1742926A (en) | Zuoci preparation for deaf and new preparing method thereof | |
| CN1775238A (en) | Anti-inflammtory anti-dysentery preparation and new preparing method | |
| CN101032524A (en) | Application of martianus dermestoides in producing oxygen-deficient resisting medicine or healthy food and the preparing method | |
| CN1833689A (en) | Asthma stop preparation and novel prepn. | |
| CN1742854A (en) | Preparation of the pod of pagoda tree and preparing method thereof | |
| CN1695728A (en) | Oral taking preparation of Chinese traditional medicine for nourishing the kidney and the lung | |
| CN1823937A (en) | Saussurea and coptis preparation and preparation method | |
| CN1742838A (en) | Xishengteng external-use medicine | |
| CN1742773A (en) | Xihuang preparation and new preparing method | |
| CN1895495A (en) | Hericiaceae contained Jianweiling capsules for stomach disease | |
| CN1927366A (en) | Traditional Chinese medicine composition for treating chronic enterogastritis | |
| CN1301095C (en) | 'Yinchai' drop pills for treating cold, fever and cough and preparation method | |
| CN1915256A (en) | Medicinal composition, preparation method and quality control method | |
| CN101926792A (en) | Phospholipid complex containing silybin di-partial succinate, preparation method and application thereof | |
| CN1541682A (en) | Insomnia treating traditional Chinese medicine preparation and its preparing process | |
| CN1868500A (en) | Medicine composition contg. tetramethylpyrazine, prepn. method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG BUCHANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BUCHANG MEDICAL SCIENCE + TECHNOLOGY DEVELOPING CO., LTD., XIANYANG CITY Effective date: 20100108 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100108 Address after: No. 369 Zhonghua West Road, Heze City, Shandong Patentee after: Shandong Buchang Pharmaceutical Co., Ltd. Address before: Shaanxi city of Xi'an province high tech high road No. 50 Nanyang International Building, 20 floor Patentee before: Buchang Medical & Drug Science & Tech. Development Co., Ltd., Xianyang |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 274000 No. 369 Zhonghua West Road, Heze City, Shandong Patentee after: Shandong Buchang Pharmaceuticals Co., Ltd. Address before: 274000 No. 369 Zhonghua West Road, Heze City, Shandong Patentee before: Shandong Buchang Pharmaceutical Co., Ltd. |